natgillin/translations-raw huggingface dataset:
Oxypurinol AUC and Cmax was not affected by food.
Hrana nije utjecala na AUC i Cmax oksipurinola.
One study in mice receiving intraperitoneal doses of 50 or 100 mg/kg on days 10 or 13 of gestation resulted in foetal abnormalities, however in a similar study in rats at 120 mg/kg on day 12 of gestation no abnormalities were observed.
Ispitivanje u miševa koji su primili intraperitonealne doze od 50 ili 100 mg/kg na 10. ili 13. dan gestacije, rezultiralo je fetalnim poremećajima, međutim, u sličnom ispitivanju na štakorima s dozom od 120 mg/kg na 12. dan gestacije nisu opaženi poremećaji.
6-mercaptopurine and azathioprine
6-merkaptopurin i azatioprin
In patients with moderate renal impairment, the incidence of renal-related adverse reactions was similar across all treatment groups: Lesinurad 200 mg (13.4%) and placebo (12.5%).
U bolesnika s umjerenim oštećenjem funkcije bubrega, incidencija nuspojava povezanih s bubrezima bila je slična u svim liječenim skupinama: Lesinurad 200 mg (13,4%) i placebo (12,5%).
With administration of allopurinol and cytostatics (e.g. cyclophosphamide, doxorubicin, bleomycin, procarbazine, alkylating agents), blood dyscrasias occur more frequently than when these active substances are administered alone.
Kod primjene alopurinola i citostatika (npr. ciklofosfamida, doksorubicina, bleomicina, prokarbazina, alkilirajućih tvari), krvna diskrazija javlja se češće nego kada se te djelatne tvari primjenjuju pojedinačno.
Duzallo is not recommended in patients with unstable angina, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled hypertension or with a recent event of myocardial infarction, stroke, or deep venous thrombosis within the last 12 months, due to insufficient data with lesinurad.
Zbog nedostatka podataka o lesinuradu, Duzallo se ne preporučuje u bolesnika s nestabilnom anginom, zatajenjem srca NYHA (New York Heart Association) stadija III ili IV, nekontroliranom hipertenzijom ili nedavnim infarktom miokarda, moždanim udarom ili dubokom venskom trombozom unutar posljednjih 12 mjeseci.
Other organs may also be affected (e.g. liver, lungs, kidneys, pancreas, myocardium, and colon).
I drugi organi mogu biti zahvaćeni (npr. jetra, pluća, bubrezi, gušterača, miokard i debelo crijevo).
EU/1/18/1300/003 30 film-coated tablets EU/1/18/1300/004 100 film-coated tablets EU/1/18/1300/006 10 film-coated tablets
EU/1/18/1300/003 30 filmom obloženih tableta EU/1/18/1300/004 100 filmom obloženih tableta EU/1/18/1300/006 10 filmom obloženih tableta
Female patients of childbearing potential should not rely on hormonal contraception alone (including oral, injectable, transdermal, and implantable forms) when taking Duzallo (see sections 4.4 and 4.5).
Žene reproduktivne dobi ne smiju se pouzdati samo u hormonsku kontracepciju (uključujući oralne, injekcijske, transdermalne oblike i implantate) tijekom uzimanja lijeka Duzallo (vidjeti dijelove 4.4 i 4.5).
Increased TSH values (>5.5 μIU/mL) were observed in patients on long-term treatment with allopurinol (5.8%) in a long term open label extension study.
U dugotrajnom nastavku otvorenog ispitivanja opažene su povećane vrijednosti TSH (> 5,5 μIU/ml) u bolesnika na dugotrajnom liječenju alopurinolom (5,8%).
EU/1/18/1300/001 30 film-coated tablets EU/1/18/1300/002 100 film-coated tablets EU/1/18/1300/005 10 film-coated tablets
EU/1/18/1300/001 30 filmom obloženih tableta EU/1/18/1300/002 100 filmom obloženih tableta EU/1/18/1300/005 10 filmom obloženih tableta
Haematuria, azotemia
Hematurija, azotemija
Adequate therapy with allopurinol will lead to dissolution of large uric acid renal pelvic stones, with the remote possibility of impaction in the ureter.
Odgovarajuća terapija alopurinolom dovest će do otapanja velikih uratnih bubrežnih kamenaca uz neznatnu mogućnost njihovog zaglavljivanja u mokraćovodu.
Patients with a history of kidney stones were permitted entry into the 12-month studies of lesinurad in combination with allopurinol.
Bolesnicima s anamnezom bubrežnih kamenaca bilo je dozvoljeno uključivanje u 12-mjesečna ispitivanja lesinurada u kombinaciji s alopurinolom.
Lesinurad is administered as a 50:50 mixture of lesinurad atropisomers.
Lesinurad se primjenjuje kao smjesa atropoizomera lesinurada u omjeru 50:50.
If no HLA-B*5801 genotyping is available for patients with Han Chinese, Thai or Korean descent, the benefits should be thoroughly assessed and considered to outweigh the possible higher risks before starting therapy.
Ako za bolesnike Han kineskog, Thai ili korejskog porijekla nije dostupna genotipizacija za HLA-B*5801, potrebno je prije započinjanja terapije temeljito procijeniti koristi i smatrati da koristi prevladavaju u odnosu na moguće povišene rizike.
Very rare - may affect up to 1 in 10,000 people - chest pain, slow heartbeat, high blood pressure or a slow pulse, - vomiting blood (recurrent hematemesis), presence of excess fat in the stool (steatorrhea), - inflammation of the mucous membranes of the mouth (stomatitis), changed stool frequency (changed bowel motions), - hair loss or discoloration, - abnormal glucose metabolism (diabetes; your doctor may wish to measure the level of sugar in your blood to check if this is happening), - high levels of cholesterol in your blood (hyperlipidaemia), - depression, - coma, - weakness, numbness, unsteadiness on your feet, unable to move muscles (paralysis) or loss of consciousness, - not able to control muscle movements (ataxia), - sensation of tingling, tickling, pricking or burning of skin (paraesthesia), - headache, dizziness, drowsiness or disturbance of your vision, - cloudiness of the eye (cataract), - a change in taste, - blood in your urine (haematuria), - male infertility or erectile dysfunction, - enlargement of the breasts, in men as well as in women, - build-up of fluid leading to swelling (oedema) particularly of your ankles, - muscle aches, - painful skin boil, - damage to the nerves which can cause numbness, pain and weakness.
Vrlo rijetko - mogu se javiti u do 1 na 10 000 osoba - bol u prsnom košu, spori otkucaji srca, visoki krvni tlak ili nizak puls, - povraćanje krvi (opetovana hematemeza), prisutnost viška masti u stolici (steatoreja), - upala sluznica u ustima (stomatitis), promijenjena učestalost stolice (promijenjeno pražnjenje crijeva), - gubitak ili promjena boje kose, - poremećeni metabolizam glukoze (dijabetes, Vaš liječnik će Vam možda izmjeriti razinu šećera u krvi radi provjere događaju li se te promjene), - visoke razine kolesterola u Vašoj krvi (hiperlipidemija), - depresija, - koma, - slabost, utrnulost, nestabilnost na nogama, nemogućnost pokretanja mišića (paraliza) ili gubitak svijesti, - nemogućnost kontroliranja mišićnih pokreta (ataksija), - osjećaj trnaca, golicanja, bockanja ili peckanja u koži (parestezija), - glavobolja, omaglica, omamljenost ili poremećaj Vašeg vida, - zamućenost oka (katarakta), - promjena okusa, - krv u Vašoj mokraći (hematurija), - muška neplodnost ili erektilna disfunkcija, - povećanje grudi u muškaraca i žena, - nakupljanje tekućine koje dovodi do oticanja (edema) naročito u Vašim gležnjevima, - bolovi u mišićima, - bolni gnojni čir na koži, - oštećenje živaca koje može uzrokovati utrnulost, bol i slabost.
Screening for HLA-B*5801 should be considered before starting treatment with allopurinol in patient subgroups where the prevalence of this allele is known to be high.
Prije započinjanja liječenja alopurinolom potrebno je razmotriti probir na HLA-B*5801 u podskupina bolesnika za koje je poznato da je prevalencija tog alela visoka.
Therefore, it is recommended that Duzallo should be used with caution in patients taking moderate inhibitors of CYP2C9.
Stoga se preporučuje oprez kada se Duzallo primjenjuje u bolesnika koji uzimaju umjerene inhibitore CYP2C9.
Continuous treatment with Duzallo decreases the frequency of gout flares.
Kontinuirano liječenje lijekom Duzallo smanjuje učestalost akutnih napadaja gihta.
Duzallo contains the active ingredients allopurinol and lesinurad.
Duzallo sadrži djelatne tvari alopurinol i lesinurad.
However, it is recommended that in patients receiving Duzallo which contains the active substance allopurinol an alternative to ampicillin or amoxicillin is used where available.
Međutim, u bolesnika koji primaju Duzallo, koji sadrži djelatnu tvar alopurinol, preporučuje se umjesto ampicilina ili amoksicilina primijeniti drugo liječenje kada je dostupno.
An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both medicinal products.
Prijavljeno je povećanje učestalosti kožnog osipa u bolesnika koji su primili ampicilin ili amoksicilin istodobno s alopurinolom u usporedbi s bolesnicima koji nisu primili ta dva lijeka.
A delayed multi-organ hypersensitivity disorder (known as hypersensitivity syndrome or DRESS) with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leucopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts) occurring in various combinations.
Sindrom odgođene višeorganske preosjetljivosti (poznat kao sindrom preosjetljivosti ili DRESS) s vrućicom, osipom, vaskulitisom, limfadenopatijom, pseudolimfomom, artralgijom, leukopenijom, eozinofilijom, hepatosplenomegalijom, abnormalnim pretragama funkcije jetre i sindromom nestajanja žučovoda (uništenje i nestanak intrahepatičkih žučovoda) javlja se u različitim kombinacijama.
Recurrent haematemesis, steatorrhoea, stomatitis, changed stool frequency
Opetovana hematemeza, steatoreja, stomatitis, promijenjena učestalost stolice
Duzallo is not recommended during breastfeeding.
Ne preporučuje se primjena lijeka Duzallo tijekom dojenja.
How to store Duzallo
Kako čuvati Duzallo
The kinetics of allopurinol are not likely to be altered other than due to deterioration in renal function (see section 5.2 renal impairment).
Promjene u farmakokinetici alopurinola nisu vjerojatne, osim u slučaju oslabljene funkcija bubrega (vidjeti dio 5.2 oštećenje funkcije bubrega).
Serious skin rashes (hypersensitivity syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis) have occured in patients taking allopurinol.
Ozbiljni kožni osipi (sindrom preosjetljivosti, Stevens-Johnsonov sindrom, toksična epidermalna nekroliza) pojavili su se u bolesnika koji uzimaju alopurinol.
In these studies, kidney stone adverse reactions (nephrolithiasis being the most frequent) were reported in patients treated with lesinurad 200 mg (0.5%) and placebo (1.2%).
U ovim ispitivanjima, nuspojave bubrežnih kamenaca (od kojih je najčešća nefrolitijaza) prijavljene su u bolesnika liječenih lesinuradom u dozi od 200 mg (0,5%) i placebom (1,2%).
Following administration of a single dose of lesinurad to individuals with renal impairment compared to those with normal renal function lesinurad Cmax and AUC, respectively, were 36% and 30% higher (200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher (200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment (eCrCL <30 mL/min).
Nakon primjene jednokratne doze lesinurada u osoba s oštećenjem funkcije bubrega, u usporedbi s onima koji imaju normalnu funkciju bubrega, vrijednosti Cmax odnosno AUC lesinurada bile su 36% odnosno 30% veće (200 mg) u bolesnika s blagim oštećenjem funkcije bubrega (eCrCL 60 do 89 ml/min), 20% odnosno 73% veće (200 mg) i 3% odnosno 50% (400 mg) veće u bolesnika s umjerenim oštećenjem funkcije bubrega (eCrCL 30 do 59 ml/min) te 13% više odnosno 113% veće (400 mg) u bolesnika s teškim oštećenjem funkcije bubrega (eCrCL < 30 ml/min).
Lesinurad 200mg + Allopurinol
 lesinurad 200 mg + alopurinol
The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patients undergoing Duzallo therapy.
Mehanizam te interakcije može se objasniti pomoću ksantin oksidaze koja je uključena u biotransformaciju teofilina u ljudi.
OUTER CARTON for 10, 30 and 100 film-coated tablets
VANJSKA KUTIJA za 10, 30 i 100 filmom obloženih tableta
Orange and slightly brownish oblong film-coated tablets with 8 x 19 mm in size.
Narančaste i blago smećkaste, duguljaste, filmom obložene tablete veličine 8 x 19 mm.
Additional signs to look for include: o ulcers of the mouth, throat, nose, genitals, conjunctivitis (red and swollen eyes) o widespread blisters or peeling of the skin o flu-like symptoms Very rare - may affect up to 1 in 10,000 people - swelling of the lips, tongue, face, throat, difficulty swallowing or breathing or red-raised itchy skin/hives (angioedema) - Duzallo may affect your blood, which can cause bruising more easily than usual, or you may get a sore throat or other signs of an infection.
Dodatni znakovi koji se moraju pratiti uključuju: o vrijedove u ustima, grlu, nosu, na spolnim organima te konjunktivitis (crvene i otečene oči) o rasprostranjene mjehuriće ili ljuštenje kože o simptome nalik gripi Vrlo rijetko - mogu se javiti u do 1 na 10 000 osoba - oticanje usnica, jezika, lica, grla, otežano gutanje ili disanje ili koža koja svrbi sa crvenim uzdignućima/koprivnjača (angioedem) - Duzallo može utjecati na Vašu krv, što može uzrokovati lakše nastajanje modrica od uobičajenog ili možete dobiti upalu grla ili druge znakove infekcije.
Each film-coated tablet contains 128.3 mg of lactose (as monohydrate).
Svaka filmom obložena tableta sadrži 128,3 mg laktoze (u obliku hidrata).
Caution is required when allopurinol is used in patients with alteration of thyroid function.
Potreban je oprez kada se alopurinol primjenjuje u bolesnika s promijenjenom funkcijom štitnjače.
Your doctor will check how well your kidneys are working before starting with Duzallo and during the Duzallo treatment.
Vaši bubrezi prije početka liječenja lijekom Duzallo i tijekom liječenja lijekom Duzallo.
Duzallo and all additional doses of allopurinol should be discontinued immediately at the first appearance of allopurinol-induced skin rash or other signs which may indicate an allergic reaction and additional medical care should be provided as needed.
Kod prve pojave kožnog osipa izazvanog alopurinolom ili drugih znakova koji mogu ukazivati na alergijsku reakciju, potrebno je odmah prekinuti primjenu lijeka Duzallo i svih dodatnih doza alopurinola i pružiti dodatnu medicinsku skrb prema potrebi.
Lesinurad 200 mg vs. placebo
Lesinurad 200 mg naspram placeba
Table 1 lists adverse reactions identified in clinical studies with patients receiving lesinurad 200 mg once daily in combination with allopurinol and those adverse reaction that are established for allopurinol alone.
Tablici 1 prikazane su nuspojave identificirane u kliničkim ispitivanjima s bolesnicima u kojih je primijenjen lesinurad u dozi od 200 mg jedanput dnevno u kombinaciji s alopurinolom te one nuspojave koje su utvrđene za alopurinol primijenjen sam.
In the pivotal clinical trials, a greater proportion of patients using lipid lowering or anti-hypertensive medicinal products that were CYP3A substrates required concomitant medicinal product change when treated with lesinurad 200 mg in combination with a xanthine oxidase inhibitor, compared with patients treated with placebo in combination with a xanthine oxidase inhibitor (35% versus 28%, respectively).
U pivotalnim je kliničkim ispitivanjima bio veći udio bolesnika u kojih je bila potrebna promjena istodobno primjenjivanog lijeka za sniženje lipida ili antihipertenzivnog lijeka koji su supstrati CYP3A kada se lesinurad primjenjivao u dozi od 200 mg u kombinaciji s inhibitorom ksantin oksidaze nego u bolesnika liječenih placebom u kombinaciji s inhibitorom ksantin oksidaze (35% naspram 28%).
Administration of Duzallo with a high-fat/high-calorie meal did not affect allopurinol AUC while Cmax was reduced by 18% and Tmax increased from 1.25 to 3 h compared to administration under fasting conditions.
Primjena lijeka Duzallo uz obrok s visokim udjelom masti/velikim brojem kalorija nije utjecala na AUC alopurinola dok se Cmax snizio za 18%, a Tmax povećao s 1,25 na 3 h u usporedbi s primjenom lijeka natašte.
Lesinurad, when combined with a xanthine oxidase inhibitor, increases uric acid excretion and decreases uric acid production resulting in greater sUA lowering.
Lesinurad primijenjen u kombinaciji s inhibitorom ksantin oksidaze povećava izlučivanje i smanjuje stvaranje mokraćne kiseline, što rezultira jačim sniženjem sUA.
Your doctor may give you other medicines to help prevent or treat the symptoms of gout attacks.
Vaš liječnik će Vam možda dati druge lijekove za sprječavanje ili liječenje simptoma napadaja gihta i reći će Vam koliko dugo trebate uzimati te druge lijekove. - ako imate poremećaje štitnjače
*** Includes the terms: renal failure, renal failure chronic and renal failure acute.
*** Uključuje pojmove: zatajenje bubrega, kronično zatajenje bubrega i akutno zatajenje bubrega.
Figure 1 Mean serum uric acid levels in pooled clinical studies with lesinurad in combination with allopurinol in patients with inadequate response (sUA ≥6 mg/dL) to allopurinol alone
Slika 1 Srednje razine mokraćne kiseline u serumu u združenim kliničkim ispitivanjima kombinacije lesinurada i alopurinola u bolesnika s nezadovoljavajućim odgovorom (sUA ≥ 6 mg/dl) u odnosu na liječenje samo alopurinolom
In each of the studies, a greater proportion of patients treated with lesinurad 200 mg in combination with allopurinol compared with placebo in combination with allopurinol achieved a serum uric acid level of less than 5 mg/dL by Month 6 (CLEAR1: 29% versus 10%; CLEAR2: 35% versus 5%).
U svakom od ispitivanja, veći udio bolesnika liječenih lesinuradom 200 mg u kombinaciji s alopurinolom, u usporedbi s onima liječenima kombinacijom placeba i alopurinola, postigao je razinu mokraćne kiseline u serumu manju od 5 mg/dl do 6. mjeseca (CLEAR1: 29% naspram 10%; CLEAR2: 35% naspram 5%).
Each film-coated tablet contains 102.6 mg of lactose (as monohydrate).
Svaka filmom obložena tableta sadrži 102,6 mg laktoze (u obliku hidrata).
Concurrent use of allopurinol and ACE inhibitors may lead to an increased risk of hypersensitivity, especially if there is pre-existing renal impairment.
Inhibitori angiotenzin konvertirajućeg enzima (ACE) Istodobna primjena alopurinola i ACE inhibitora može dovesti do povećanog rizika od preosjetljivosti, naročito ako već postoji oštećenje funkcije bubrega.
Administration of Duzallo with a high-fat/high-calorie meal did not affect lesinurad AUC while Cmax was reduced by 46% and Tmax increased from 2 to 4.5 h compared to administration under fasting conditions.
Primjena lijeka Duzallo uz obrok s visokim udjelom masti/velikim brojem kalorija nije utjecala na AUC lesinurada dok se Cmax snizio za 46%, a Tmax povećao s 2 na 4,5 h u usporedbi s primjenom lijeka natašte.
In two 12-month placebo-controlled trials of lesinurad in combination with allopurinol versus allopurinol alone (placebo), serum creatinine elevations between 1.5-fold and 2-fold over baseline occurred in 4.4% of patients on lesinurad 200 mg and 2.2% on placebo; serum creatinine elevations 2fold or greater over baseline occurred in 1.5% of patients on lesinurad 200 mg and 0% on placebo.
U dva 12-mjesečna placebom kontrolirana ispitivanja lesinurada u kombinaciji s alopurinolom naspram samog alopurinola (uz placebo), razina serumskog kreatinina povisila se za 1,5 do 2 puta u odnosu na početnu vrijednost u 4,4% bolesnika liječenih lesinuradom 200 mg te 2,2% bolesnika liječenih placebom; do dvostrukog ili većeg povišenja razine serumskog kreatinina u odnosu na početnu vrijednost došlo je u 1,5% bolesnika u kojih je primjenjivan lesinurad 200 mg i u 0% bolesnika koji su primali placebo.
Re-challenge should not be undertaken in patients with hypersensitivity syndrome.
Ponovno uvođenje lijeka ne smije se provesti u bolesnika sa sindromom preosjetljivosti.
Duzallo 200 mg / 200 mg tablets are available in blister packs of 10, 30 and 100 tablets.
Duzallo 200 mg / 200 mg tablete dostupne su u blister pakiranjima od 10, 30 i 100 tableta.
An interaction between allopurinol and coumarins has been seen under experimental conditions.
U eksperimentalnim uvjetima uočena je interakcija između alopurinola i kumarina.
The film-coated tablets are engraved with “LES200” and “ALO300” on one side.
Filmom obložene tablete imaju utisnutu oznaku "LES200" i "ALO300" s jedne strane.
The stability of the sustained response was demonstrated with a greater proportion of patients treated with lesinurad 200 mg in combination with allopurinol achieving the target serum uric acid level at each visit for 3 consecutive months (Months 4, 5 and 6) compared to patients treated with placebo in combination with allopurinol (see Table 3).
Stabilnost održanog odgovora na liječenje dokazana je s većim udjelom bolesnika liječenih lesinuradom u dozi od 200 mg u kombinaciji s alopurinolom koji su postigli ciljnu razinu mokraćne kiseline u serumu pri svakom posjetu tijekom 3 uzastopna mjeseca (4., 5. i 6. mjesec) u usporedbi s bolesnicima liječenima placebom u kombinaciji s alopurinolom (vidjeti Tablicu 3).
Duzallo 300 mg / 200 mg tablets are available in blister packs of 10, 30 and 100 tablets.
Duzallo 300 mg / 200 mg tablete dostupne su u blister pakiranjima od 10, 30 i 100 tableta.
Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Duzallo is co-administered.
Hormonski kontraceptivi, uključujući oralne, injekcijske i transdermalne oblike te implantate, mogu biti nepouzdani kada se primjenjuju istodobno s lijekom Duzallo.
Gout flare prophylaxis needs to be considered (see section 4.2).
Potrebno je razmotriti profilaksu za akutne napadaje gihta (vidjeti dio 4.2).
Duzallo is contraindicated in patients with severe renal impairment (CrCL less than 30 ml/min), with end-stage renal disease, in patients on dialysis or in kidney transplant recipients (see sections 4.3 and 4.4).
Duzallo je kontraindiciran u bolesnika s teškim oštećenjem funkcije bubrega (CrCL manji od 30 ml/min), sa završnim stadijem bolesti bubrega, u bolesnika na dijalizi ili u primatelja presatka bubrega (vidjeti dijelove 4.3 i 4.4).
A reduction in the dose of allopurinol is therefore required in patients with renal impairment (see section 4.2).
Stoga je potrebno smanjiti dozu alopurinola u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 4.2).
The film-coated tablets are engraved with “LES200” and “ALO200” on one side.
Filmom obložene tablete imaju utisnutu oznaku "LES200" i "ALO200" s jedne strane.
Patients who are known or suspected to be CYP2C9 poor metabolisers based on previous history or experience with other CYP2C9 substrates should use Duzallo with caution (see section 4.4).
Duzallo je potrebno s oprezom primijeniti u bolesnika za koje je poznato ili se sumnja da su spori CYP2C9 metabolizatori, s obzirom na prethodnu anamnezu ili iskustvo s drugim supstratima CYP2C9 (vidjeti dio 4.4).
The signs may include: Uncommon - may affect up to 1 in 100 people - pain in your side (below your ribs and above your hipbone), - feeling sick (nausea), - being sick (vomiting), - changes in urination or difficulty urinating, - feeling tired or unwell or loss of appetite.
Znakovi mogu uključivati: Manje često - mogu se javiti u do 1 na 100 osoba - bol u slabinama (ispod rebara i iznad zdjelične kosti), - mučnina, - povraćanje, - promjene mokrenja ili poteškoće s mokrenjem, - osjećaj umora ili loše osjećanje ili gubitak apetita.